Strategic Partners Council
The Critical Mass Partnership Council brings together leaders and stakeholders in all industries to work as partners in the fight to advance young adult cancer care in the United States. The Council will meet regularly to find areas where we can introduce and draft policies at local, state, and federal levels to ensure every American – no matter their age – can both survive and thrive after a cancer diagnosis.
Genentech: Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. They are among the world’s leading biotech companies, with multiple products on the market and a promising development pipeline.
Friend of Critical Mass
Amgen: Amgen believes in a “biology first” approach. They use cutting-edge science and technology to study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from diseases. Amgen believes the cure for disease can be found inside each and every one of us.
The Char and Chuck Fowler Family Foundation: In honor of Angie Fowler, who died of melanoma at age 14, The Char and Chuck Fowler Family Foundation has dedicated a large portion of their giving to focus on adolescent and young adult (AYA) cancer issues. Since 2001, the Foundation and its trustees has granted more than $26 million toward research, treatment and for the continuum of care for AYA patients. The largest grant was made in 2011 to establish The Angie Fowler Child & Young Adult Cancer Institute at University Hospitals Rainbow Babies & Children’s Hospital in Cleveland, Ohio.
Leukemia and Lymphoma Society: The mission of The Leukemia & Lymphoma Society (LLS) is: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS exists to find cures and ensure access to treatments for blood cancer patients. We are the voice for all blood cancer patients and we work to ensure access to treatments for all blood cancer patients.